Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Blackhawk Growth Corp BLRZF


Primary Symbol: C.BLR Alternate Symbol(s):  C.BLR.WT

Blackhawk Growth Corp. is a Canada-based investment holding company. The Company invests in equity and debt instruments of companies to generate positive returns for shareholders. It focuses on investing in multiple companies across a variety of sectors across North America. The Company has focused its investments on the health, cannabis and cannabidiol (CBD) industries, in both Canada and the... see more

CSE:BLR - Post Discussion

Blackhawk Growth Corp > MindBio Invests NZ$2.3M to Fast Track Phase2 Clinical Trials
View:
Post by bveilleu on Mar 10, 2022 6:17am

MindBio Invests NZ$2.3M to Fast Track Phase2 Clinical Trials

Vancouver, British Columbia - TheNewswire - March 10, 2022 - Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its 100% owned subsidiary, MindBio Therapeutics Pty Ltd. (“MindBio”), has invested NZ$2,300,000 at a world class Australasian University to advance its psychedelics microdosing clinical trials.  

MindBio is investing in world-class facilities to fast track its microdosing clinical trials.  MindBio’s Phase 1 clinical trial microdosing LSD (Lysergic Acid Diethylamide) to 80 patients at home is due for completion shortly.  Two continuation studies will follow from the NZ$2,300,000 investment including a Phase 2 clinical trial microdosing LSD in patients with major depressive disorder and a Phase 2 clinical trial microdosing LSD in late-stage cancer patients starting this year.

These clinical trials have also received government grants amounting to NZ$800,000 in funding to date to support this important clinical research into these emerging treatments.

This funding helps to accelerate intellectual property development in psychedelic microdosing, associated technology and important clinical trial work for determining safety and efficacy across different patient groups.

“MindBio is leading the charge on clinical trials of microdosing psychedelics,” says Frederick Pels, CEO of Blackhawk Growth. “With our Phase 1 clinical trial near completion in addition to substantial progress on our two Phase 2 clinical trials, it puts MindBio ahead of many of its peers in the development of intellectual property that one day may lead to helping patients with mental health conditions.”

 

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics, Digital Mind Therapeutics as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities